Karyopharm, Deep in Debt, to Sell Itself in Bankruptcy

Karyopharm files bankruptcy, to merge with Ayrmid (KPTI:NASDAQ)

Karyopharm Therapeutics plans bankruptcy and a merger with Ayrmid, backed by $55M in financing.

Karyopharm, deep in debt, to sell itself in bankruptcy

The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

Karyopharm Enters Chapter 11 in Planned Merger With Ayrmid

Karyopharm filed for Chapter 11 under a plan to merge with Ayrmid, with competing bids allowed and closing targeted for the first quarter of 2027.

Karyopharm announces planned merger with Ayrmid amid Chapter 11 bankruptcy filing

The merger is not final and other companies will be able to bid for Karyopharm’s assets

Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird

With few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeutics, maker of the multiple myeloma drug ...